arrowhead läuft - zu recht

Feb 15, 2018
Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT
ir.arrowheadpharma.com/releasedetail.cfm?ReleaseID=1057707

Feb 22, 2018
Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
ir.arrowheadpharma.com/releasedetail.cfm?ReleaseID=1058336

Feb 22, 2018
3:10 PM UK
SMI RNA Therapeutics Conference
Location: London
files.shareholder.com/downloads/...rowhead_Pharmaceuticals.pdf

Feb 27 - Mar 1, 2018
AsiaTIDES: Oligonucleotide and Peptide Therapeutics

Arrowhead’s TRiM™ Delivery System – Potent, Modular, and Versatile for RNAi Bruce D. Given,
ir.arrowheadpharma.com/static-files/...-4cc3-86ee-142fc21906c1


Recent Advances in RNAi Therapeutics at Arrowhead Pharmaceuticals Zhen Li, Ph.D., SVP Chemistry and Manufacturing
Location:
Kyoto, Japan
ir.arrowheadpharma.com/static-files/...-44ba-b9bf-b40175cc5017

$ARWR vs. $ALNY - @BioBoyScout's Equity Research Report, A Comparative Analysis, March 8, 2018.
drive.google.com/file/d/1Q14L9dBLn3hR8hzcUmgzW4ce2I39py4x/view

March 12, 2018 07:30 AM Eastern Daylight Time

Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
www.businesswire.com/news/home/20180312005310/en/

www.genengnews.com/gen-articles/...-the-liver-and-beyond/6275

Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B
March 27, 2018 07:30 AM Eastern Daylight Time
www.businesswire.com/news/home/...sing-Phase-12-Study-ARO-HBV

March 27, 2018 4:15 AM EDT
Jefferies initiates coverage on Arrowhead Research (NASDAQ: ARWR) with a Buy rating and a price target of $10.00.Analyst Maury Raycroft .
www.streetinsider.com/Analyst+Comments/...t+Buy/13986265.html

Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™
March 28, 2018 07:30 AM Eastern Daylight Time
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present clinical and pre-clinical data on the company’s investigational medicines for the treatment of chronic hepatitis B infection (ARC-520 and ARO-HBV) and liver disease associated with alpha-1 antitrypsin deficiency (ARO-AAT), at The International Liver Congress™ 2018, the annual meeting of the European Association for the Study of the Liver (EASL), being held in Paris from April 11-15, 2018.
www.businesswire.com/news/home/...-Liver#.WruBGQGrnSo.twitter

Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™
April 11, 2018 07:00 AM Eastern Daylight Time
www.businesswire.com/news/home/20180411005375/en/
Key results include the following:

   One HBeAg-negative patient serocleared HBsAg post ARC-520
   Mild ALT changes off ARC-520 therapy coincided with sustained host responses in 2/3 HBeAg- positive and 2/5 HBeAg-negative patients
   A single dose of ARC-520 in combination with ETV reduced HBsAg for up to 44 weeks
   Multiple doses of ARC-520 resulted in additional HBsAg reductions in all patients by as much 5.3 Log10
   ARC-520 in combination with ETV was effective at rapidly suppressing HBV DNA

Apr 25, 2018 4:00 PM EDT
World Orphan Drug Congress USA 2018
ir.arrowheadpharma.com/static-files/...-4c68-8bd2-9918dfc44cdd

Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics
www.businesswire.com/news/home/20180501005558/en/

American Thoracic Society (ATS) 2018 International Conference – San Diego, May 18-23, 2018

May 21, 9:15 a.m.-4:15 p.m. PDT – Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver a poster presentation titled, “Targeting αENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis.” In this presentation, Dr. Bush will present new preclinical data on ARO-ENaC, formerly referred to as ARO-Lung1, targeting the epithelial sodium channel alpha subunit (αENaC) for the treatment of cystic fibrosis.  

Arrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Fiscal Q2 2018 Results - Earnings Call Transcript
seekingalpha.com/article/...cal-q2-2018-results-earnings-call

www.finanzen.net/analyse/...erweight-Cantor_Fitzgerald_643662

www.nasdaq.com/de/symbol/arwr/real-time

RNA interference therapies could be on the cusp of success
www.pharmaceutical-journal.com/...of-success/20204853.article

Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis
May 21, 2018 07:30 AM Eastern Daylight Time
www.businesswire.com/news/home/20180521005437/en/

Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences
May 30, 2018 07:25 AM Eastern Daylight Time
www.businesswire.com/news/home/20180530005534/en/

Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV
May 30, 2018 07:30 AM Eastern Daylight Time
www.businesswire.com/news/home/20180530005538/en/

Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
June 18, 2018 07:30 AM Eastern Daylight Time
www.businesswire.com/news/home/20180618005327/en/

Two planned cohorts at a dose of 400 mg were eliminated because maximal activity appeared to occur at lower doses than expected.

Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency

June 27, 2018 07:30 AM Eastern Daylight Time
www.businesswire.com/news/home/20180627005432/en/

Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference
June 29, 2018 07:30 AM Eastern Daylight Time
www.businesswire.com/news/home/20180629005141/en/

Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment from Amgen
August 01, 2018 07:30 AM Eastern Daylight Time
www.businesswire.com/news/home/...0-Million-Milestone-Payment

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $10 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study. Amgen is evaluating AMG 890 in a Phase 1 clinical study designed to assess its safety in volunteers with elevated levels of lipoprotein (a) (Lp(a)). Emerging research has shown that elevated levels of Lp(a) are strongly associated with cardiovascular disease. AMG 890 is an RNAi therapeutic designed to lower Lp(a) for the treatment of cardiovascular disease.  

madison-com.cdn.ampproject.org/v/s/...-b8ac-9a3f9f42ba26.html
Auszug

Arrowhead plans to seek federal regulatory approval to start clinical trials on three more products before the end of the year. Two are cardiometabolic — referring to cardiovascular disease and diabetes — and one targets cystic fibrosis, said Vincent Anzalone, vice president of finance and investor relations. A prospective drug against kidney cancer is on the agenda for 2019 and there is “a handful of others beyond that,” he said, all built on the targeted RNAi molecule platform.